Disease | N. SNPs d | DSI v | DPI v | Chr | Position | Consequence | Alleles | Class | AFEXOME | AFGENOME | Score vda | EI vda | N. PMIDs | First Ref. | Last Ref. | ||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mucocutaneous Lymph Node Syndrome
|
195 | 0.576 | 0.720 | 6 | 43784799 | 3 prime UTR variant | C/T | snv | 0.13 | 0.020 | 1.000 | 2 | 2006 | 2012 | |||||
Diabetic Retinopathy
|
213 | 0.576 | 0.720 | 6 | 43784799 | 3 prime UTR variant | C/T | snv | 0.13 | 0.030 | 1.000 | 3 | 2014 | 2017 | |||||
Conventional (Clear Cell) Renal Cell Carcinoma
|
222 | 0.576 | 0.720 | 6 | 43784799 | 3 prime UTR variant | C/T | snv | 0.13 | 0.030 | 1.000 | 3 | 2013 | 2017 | |||||
Gestational Diabetes
|
224 | 0.576 | 0.720 | 6 | 43784799 | 3 prime UTR variant | C/T | snv | 0.13 | 0.010 | 1.000 | 1 | 2019 | 2019 | |||||
Endometriosis
|
274 | 0.576 | 0.720 | 6 | 43784799 | 3 prime UTR variant | C/T | snv | 0.13 | 0.040 | 0.750 | 4 | 2008 | 2020 | |||||
Bladder Neoplasm
|
281 | 0.576 | 0.720 | 6 | 43784799 | 3 prime UTR variant | C/T | snv | 0.13 | 0.020 | 1.000 | 2 | 2019 | 2019 | |||||
Hypothyroidism
|
283 | 0.576 | 0.720 | 6 | 43784799 | 3 prime UTR variant | C/T | snv | 0.13 | 0.010 | 1.000 | 1 | 2012 | 2012 | |||||
Renal Cell Carcinoma
|
288 | 0.576 | 0.720 | 6 | 43784799 | 3 prime UTR variant | C/T | snv | 0.13 | 0.030 | 1.000 | 3 | 2013 | 2017 | |||||
Chronic Lymphocytic Leukemia
|
291 | 0.576 | 0.720 | 6 | 43784799 | 3 prime UTR variant | C/T | snv | 0.13 | 0.010 | 1.000 | 1 | 2014 | 2014 | |||||
Carcinoma of bladder
|
309 | 0.576 | 0.720 | 6 | 43784799 | 3 prime UTR variant | C/T | snv | 0.13 | 0.020 | 1.000 | 2 | 2019 | 2019 | |||||
Malignant neoplasm of urinary bladder
|
316 | 0.576 | 0.720 | 6 | 43784799 | 3 prime UTR variant | C/T | snv | 0.13 | 0.020 | 1.000 | 2 | 2019 | 2019 | |||||
Glioma
|
353 | 0.576 | 0.720 | 6 | 43784799 | 3 prime UTR variant | C/T | snv | 0.13 | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||
Polycystic Ovary Syndrome
|
363 | 0.576 | 0.720 | 6 | 43784799 | 3 prime UTR variant | C/T | snv | 0.13 | 0.020 | 1.000 | 2 | 2019 | 2019 | |||||
Malignant neoplasm of stomach
|
615 | 0.576 | 0.720 | 6 | 43784799 | 3 prime UTR variant | C/T | snv | 0.13 | 0.010 | 1.000 | 1 | 2009 | 2009 | |||||
Stomach Carcinoma
|
652 | 0.576 | 0.720 | 6 | 43784799 | 3 prime UTR variant | C/T | snv | 0.13 | 0.010 | 1.000 | 1 | 2009 | 2009 | |||||
Age related macular degeneration
|
663 | 0.576 | 0.720 | 6 | 43784799 | 3 prime UTR variant | C/T | snv | 0.13 | 0.030 | 1.000 | 3 | 2013 | 2016 | |||||
Ischemic stroke
|
704 | 0.576 | 0.720 | 6 | 43784799 | 3 prime UTR variant | C/T | snv | 0.13 | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||
Diabetes
|
710 | 0.576 | 0.720 | 6 | 43784799 | 3 prime UTR variant | C/T | snv | 0.13 | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||
Non-Small Cell Lung Carcinoma
|
712 | 0.576 | 0.720 | 6 | 43784799 | 3 prime UTR variant | C/T | snv | 0.13 | 0.020 | 1.000 | 2 | 2010 | 2012 | |||||
Diabetes Mellitus
|
824 | 0.576 | 0.720 | 6 | 43784799 | 3 prime UTR variant | C/T | snv | 0.13 | 0.010 | 1.000 | 1 | 2018 | 2018 | |||||
Multiple Myeloma
|
865 | 0.576 | 0.720 | 6 | 43784799 | 3 prime UTR variant | C/T | snv | 0.13 | 0.010 | 1.000 | 1 | 2012 | 2012 | |||||
Liver carcinoma
|
942 | 0.576 | 0.720 | 6 | 43784799 | 3 prime UTR variant | C/T | snv | 0.13 | 0.010 | 1.000 | 1 | 2019 | 2019 | |||||
Parkinson Disease
|
990 | 0.576 | 0.720 | 6 | 43784799 | 3 prime UTR variant | C/T | snv | 0.13 | 0.010 | 1.000 | 1 | 2016 | 2016 | |||||
Multiple Sclerosis
|
1022 | 0.576 | 0.720 | 6 | 43784799 | 3 prime UTR variant | C/T | snv | 0.13 | 0.010 | 1.000 | 1 | 2017 | 2017 | |||||
Malignant neoplasm of prostate
|
1082 | 0.576 | 0.720 | 6 | 43784799 | 3 prime UTR variant | C/T | snv | 0.13 | 0.020 | 0.500 | 2 | 2014 | 2019 |